Developmental Aspects of Human Hepatic Drug Glucuronidation in Young Children and Adults

Overview

Journal Gut

Specialty Gastroenterology

Date 2002 Jan 15

PMID 11788570

Citations 101

Authors

C P Strassburg

A Strassburg

S Kneip

A Barut

R H Tukey

B Rodeck

M P Manns

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The liver represents one of the major sites of human glucuronidation. Many therapeutic drugs are substrates for UDP-glucuronosyltransferases (UGT) leading to the formation of usually inactive glucuronides. Hepatic glucuronidation undergoes significant changes during fetal and neonatal development requiring age adapted drug therapy. Regulation of individual UGT genes during hepatic development has not been defined.

Subjects And Methods: Expression of 13 UGT genes and glucuronidation activities were analysed in 16 paediatric liver samples (aged 7-24 months), two fetal samples, and 12 adult liver samples (aged 25-75 years) using duplex reverse transcription-polymerase chain reaction, western blot, and specific catalytic UGT activity assays.

Results: No UGT transcripts were detected in fetal liver at 20 weeks' gestation. In contrast, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, and UGT2B15 transcripts were present without variation in all 28 hepatic samples after six months of age. Significantly lower expression of UGT1A9 and UGT2B4 mRNA was identified in paediatric liver. Hepatic glucuronidation activity in children aged 13-24 months was found to be lower than in adults for ibuprofen (24-fold), amitriptyline (16-fold), 4-tert-butylphenol (40-fold), estrone (15-fold), and buprenorphine (12-fold).

Conclusions: An early phase characterised by the appearance of UGT gene transcripts and a later phase characterised by upregulation of UGT expression is demonstrated during human hepatic development. The differential regulation of UGT1A9 and UGT2B4 expression extends beyond two years of age and is capable of influencing hepatic glucuronidation of common therapeutic drugs in children. The development of hepatic UGT activities is significant for paediatric drug therapy and the prevention of adverse drug effects.

Citing Articles

Knowledge, attitudes and practices regarding medication splitting and crushing among the general public in Jordan: a cross-sectional study.

Jaradat A, Alomari E, Bayan M, Naser A BMJ Open. 2024; 14(11):e087109.

PMID: 39542471 PMC: 11575342. DOI: 10.1136/bmjopen-2024-087109.

Drug-induced liver injury in children: A nationwide cohort study from China.

Lai R, Li X, Zhang J, Chen J, Yang C, Xie W JHEP Rep. 2024; 6(8):101102.

PMID: 39105181 PMC: 11298914. DOI: 10.1016/j.jhepr.2024.101102.

Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.

Walton M, Wagner J Genes (Basel). 2024; 15(3).

PMID: 38540438 PMC: 10969836. DOI: 10.3390/genes15030379.

Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives.

Zhang W, Zhang Q, Cao Z, Zheng L, Hu W Pharmaceutics. 2023; 15(12).

PMID: 38140105 PMC: 10747965. DOI: 10.3390/pharmaceutics15122765.

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.

Dinh J, Johnson T, Grimstein M, Lewis T Pharmaceutics. 2023; 15(11).

PMID: 38004559 PMC: 10675397. DOI: 10.3390/pharmaceutics15112579.

References

Bock K, Lilienblum W, von Bahr C . Studies of UDP-glucuronyltransferase activities in human liver microsomes. Drug Metab Dispos. 1984; 12(1):93-7. View

Strassburg C, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey R . Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem. 2000; 275(46):36164-71. DOI: 10.1074/jbc.M002180200. View

Matern H, Matern S, Gerok W . Formation of bile acid glucosides by a sugar nucleotide-independent glucosyltransferase isolated from human liver microsomes. Proc Natl Acad Sci U S A. 1984; 81(22):7036-40. PMC: 392071. DOI: 10.1073/pnas.81.22.7036. View

Peters W, Allebes W, Jansen P, Poels L, Capel P . Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology. 1987; 93(1):162-9. DOI: 10.1016/0016-5085(87)90329-5. View

Leakey J, HUME R, Burchell B . Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem J. 1987; 243(3):859-61. PMC: 1147936. DOI: 10.1042/bj2430859. View

Pacifici G, Back D . Sulphation and glucuronidation of ethinyloestradiol in human liver in vitro. J Steroid Biochem. 1988; 31(3):345-9. DOI: 10.1016/0022-4731(88)90360-3. View

Pacifici G, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro G . Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica. 1988; 18(7):849-56. DOI: 10.3109/00498258809041723. View

Coughtrie M, Burchell B, Leakey J, HUME R . The inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol. 1988; 34(6):729-35. View

Burchell B, Coughtrie M, Jackson M, Harding D, Fournel-Gigleux S, Leakey J . Development of human liver UDP-glucuronosyltransferases. Dev Pharmacol Ther. 1989; 13(2-4):70-7. DOI: 10.1159/000457587. View

10.

Pacifici G, Franchi M, Giuliani L, Rane A . Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus. Dev Pharmacol Ther. 1989; 14(2):108-14. View

11.

Matern H, Lappas N, Matern S . Isolation and characterization of hyodeoxycholic-acid: UDP-glucuronosyltransferase from human liver. Eur J Biochem. 1991; 200(2):393-400. DOI: 10.1111/j.1432-1033.1991.tb16197.x. View

12.

Burchell B, Nebert D, Nelson D, Bock K, Iyanagi T, Jansen P . The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol. 1991; 10(7):487-94. DOI: 10.1089/dna.1991.10.487. View

13.

Wooster R, Sutherland L, Ebner T, Clarke D, da Cruz e Silva O, Burchell B . Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family. Biochem J. 1991; 278 ( Pt 2):465-9. PMC: 1151367. DOI: 10.1042/bj2780465. View

14.

Rhodes K, Henry N . Antibiotic therapy for severe infections in infants and children. Mayo Clin Proc. 1992; 67(1):59-68. DOI: 10.1016/s0025-6196(12)60280-8. View

15.

Tukey R, Strassburg C . Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000; 40:581-616. DOI: 10.1146/annurev.pharmtox.40.1.581. View

16.

Sharp S, Mak L, Smith D, Coughtrie M . Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs--implications for adverse drug reactions. Xenobiotica. 1992; 22(1):13-25. DOI: 10.3109/00498259209053098. View

17.

Ebner T, Burchell B . Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos. 1993; 21(1):50-5. View

18.

Wooster R, Ebner T, Sutherland L, Clarke D, Burchell B . Drug and xenobiotic glucuronidation catalysed by cloned human liver UDP-Glucuronosyltransferases stably expressed in tissue culture cell lines. Toxicology. 1993; 82(1-3):119-29. DOI: 10.1016/0300-483x(93)02607-i. View

19.

Burchell B, Coughtrie M, Jansen P . Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report of the Seventh International Workshop on Glucuronidation, September 1993, Pitlochry, Scotland. Hepatology. 1994; 20(6):1622-30. DOI: 10.1002/hep.1840200636. View

20.

Debinski H, Lee C, Danks J, Mackenzie P, Desmond P . Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995; 108(5):1464-9. DOI: 10.1016/0016-5085(95)90695-9. View